|
1
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujita H: History of lymphadenectomy for
esophageal cancer and the future prospects for esophageal cancer
surgery. Surg Today. 45:140–149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakajima M and Kato H: Treatment options
for esophageal squamous cell carcinoma. Expert Opin Pharmacother.
14:1345–1354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akutsu Y and Matsubara H:
Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.
Surg Today. 45:1360–1365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kojima T, Hara H, Yamaguchi K, Hironaka S,
Iwasa S, Kato K, Tsushima T, Yasui H, Ura T, Muro K, et al: Phase
II study of nivolumab (ONO-4538/BMS-936558) in patients with
esophageal cancer: Preliminary report of overall survival. J Clin
Oncol. 34 Suppl 4S:abstr TPS1752016. View Article : Google Scholar
|
|
10
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carbognin L, Pilotto S, Milella M, Vaccaro
V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D,
Chilosi M, et al: Differential activity of nivolumab, pembrolizumab
and MPDL3280A according to the tumor expression of programmed
death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma,
lung and genitourinary cancers. PLoS One. 10:e01301422015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hewish M, Lord CJ, Martin SA, Cunningham D
and Ashworth A: Mismatch repair deficient colorectal cancer in the
era of personalized treatment. Nat Rev Clin Oncol. 7:197–208. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tzao C, Hsu HS, Sun GH, Lai HL, Wang YC,
Tung HJ, Yu CP, Cheng YL and Lee SC: Promoter methylation of the
hMLH1 gene and protein expression of human mutL homolog 1 and human
mutS homolog 2 in resected esophageal squamous cell carcinoma. J
Thorac Cardiovasc Surg. 130:13712005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gryfe R, Kim H, Hsieh ET, Aronson MD,
Holowaty EJ, Bull SB, Redston M and Gallinger S: Tumor
microsatellite instability and clinical outcome in young patients
with colorectal cancer. N Engl J Med. 342:69–77. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ward R, Meagher A, Tomlinson I, O'Connor
T, Norrie M, Wu R and Hawkins N: Microsatellite instability and the
clinicopathological features of sporadic colorectal cancer. Gut.
48:821–829. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sargent DJ, Marsoni S, Monges G, Thibodeau
SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri
V, et al: Defective mismatch repair as a predictive marker for lack
of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Popat S, Hubner R and Houlston RS:
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. Wiley; 2009
|
|
19
|
Makino T, Yamasaki M, Miyata H, Yoshioka
S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M and Doki
Y: p53 mutation status predicts pathological response to
chemoradiotherapy in locally advanced esophageal cancer. Ann Surg
Oncol. 17:804–811. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Japan Esophageal Society, . Japanese
Classification of Esophageal Cancer, tenth edition: part I.
Esophagus. 6:1–25. 2009. View Article : Google Scholar
|
|
21
|
Japan Esophageal Society, . Japanese
classification of esophageal cancer, tenth edition: parts II and
III. Esophagus. 6:71–94. 2009. View Article : Google Scholar
|
|
22
|
Kishi K, Doki Y, Yano M, Yasuda T,
Fujiwara Y, Takiguchi S, Kim S, Higuchi I and Monden M: Reduced
MLH1 expression after chemotherapy is an indicator for poor
prognosis in esophageal cancers. Clin Cancer Res. 9:4368–4375.
2003.PubMed/NCBI
|
|
23
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lanza G, Gafa R, Maestri I, Santini A,
Matteuzzi M and Cavazzini L: Immunohistochemical pattern of
MLH1/MSH2 expression is related to clinical and pathological
features in colorectal adenocarcinomas with microsatellite
instability. Mod Pathol. 15:741–749. 2002. View Article : Google Scholar : PubMed/NCBI
|
